Shengnuo Biotech (688117): Rapid growth in Q3 performance, large order delivery boosts medium- to long-term development

Open Source SecuritiesOct 31, 2024 18:33

Shengnuo Biotech (688117): Pioneer in the field of peptides, overseas layout creates room for long-term growth

Guosheng SecuritiesOct 31, 2024 00:00

Shengnuo Biotech (688117): Production capacity expansion is poised for rapid growth of peptide drugs awaiting development

Southwest SecuritiesOct 8, 2024 00:00

Shengnuo Biotech (688117): New orders are expected to increase the company's performance and continue to improve in the medium to long term

China Post SecuritiesSep 18, 2024 19:16

Shengnuo Biotech (688117): Deepening the peptide industry chain, steady business growth, continuous release of GLP-1 peptide raw materials

Sep 12, 2024 07:26

Shengnuo Biotech (688117): More than 20 years of intensive cultivation of peptides, production capacity and orders are expected to enter the accelerated climbing phase

Aug 30, 2024 00:00

Shengnuo Biotech (688117): Pioneer in the field of peptides, full industry chain layout seizes GLP-1 historical opportunities

Aug 26, 2024 13:01

Shengnuo Biotech (688117): Leading domestic peptide drug leading API, formulation, and CDMO business collaborative development

Aug 12, 2024 16:11

Shengnuo Biology (688117): Comprehensive layout in the field of peptides, production capacity release welcomes rapid development

Aug 7, 2024 00:00

Shengnuo Biotech (688117): The layout of the entire peptide industry chain, capacity release and implementation, is expected to accelerate growth

Aug 2, 2024 18:21

Shengnuo Biotech (688117): Production capacity is about to be implemented, it is recommended to focus on major trends in the GLP-1 industry

Aug 2, 2024 07:36

Shengnuo Biotech (688117): R&D Investment & Procurement Affects Q2 Profit Performance R&D and Capacity Construction to Build Competitive Barriers

Jul 31, 2024 15:56

Shengnuo Biotech (688117): New peptide production capacity will soon be released, export volume is worth looking forward to

Jul 30, 2024 00:00

Shengnuo Biotech (688117): Deeply involved in the field of peptides, the expansion of multiple business segments is imminent

May 6, 2024 12:56

Huafu Securities released a research report on April 24 stating that it gave Shengnuo Biotech (688117.SH) a purchase rating, and the target price was 35.7 yuan. The main reasons for the rating include: 1) GLP-1 is driving the expansion of the peptide mark

Zhitong FinanceApr 24, 2024 20:30

Shengnuo Biotech (688117) Company Information Update Report: Profit Side Flexibility Is Gradually Unleashed, New Production Capacity Is About to Be Implemented to Break Through Supply Bottlenecks

Apr 24, 2024 16:06

Open Source Securities released a research report on April 23 stating that it gave Shengnuo Biotech (688117.SH) a purchase rating. The main reasons for the rating include: 1) the gradual release of profit-side flexibility, and the overall steady developme

Zhitong FinanceApr 24, 2024 12:42

Huafu Securities released a research report on April 23 stating that it gave Shengnuo Biotech (688117.SH) a purchase rating, and the target price was 35.7 yuan. The main reasons for the rating include: 1) incident: the company released the 2023 annual rep

Zhitong FinanceApr 24, 2024 07:35

Shengnuo Biotech (688117): Steady performance growth is expected to be implemented in new production capacity to drive faster performance

Apr 23, 2024 14:31

Guojin Securities released a research report on April 23 stating that it gave Shengnuo Biotech (688117.SH) an increase rating. The main reasons for the rating include: 1) the comprehensive peptide layout consolidates the first-mover advantage, and the lay

Zhitong FinanceApr 23, 2024 13:39